WuXi PharmaTech receives GLP statement for Suzhou Toxicology facility

WuXi PharmaTech announced that its toxicology facility in Suzhou had received a statement of Good Laboratory Practice, or GLP, from the Belgium Scientific Institute of Public Health after successfully passing two GLP inspections conducted by the Belgium GLP Monitorate. Good Laboratory Practice is a quality system concerned with the organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported. The receipt of this GLP statement is an important acknowledgement by a full OECD/EC member monitoring authority about the capability of the Suzhou facility to carry out toxicology and mutagenicity studies and analytical and clinical chemistry testing with respect to OECD and EC principles of GLP.